Cancer regression in patients after transfer of genetically engineered lymphocytes

Richard A. Morgan, Mark E. Dudley, John R. Wunderlich, Marybeth S. Hughes, James C. Yang, Richard M. Sherry, Richard E. Royal, Suzanne Topalian, Udai S. Kammula, Nicholas P. Restifo, Zhili Zheng, Azam Nahvi, Christiaan R. De Vries, Linda J. Rogers-Freezer, Sharon A. Mavroukakis, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

Through the adoptive transfer of lymphocytes after host immunodepletion, it is possible to mediate objective cancer regression in human patients with metastatic melanoma. However, the generation of tumor-specific T cells in this mode of immunotherapy is often limiting. Here we report the ability to specifically confer tumor recognition by autologous lymphocytes from peripheral blood by using a retrovirus that encodes a T cell receptor. Adoptive transfer of these transduced cells in 15 patients resulted in durable engraftment at levels exceeding 10% of peripheral blood lymphocytes for at least 2 months after the infusion. We observed high sustained levels of circulating, engineered cells at 1 year after infusion in two patients who both demonstrated objective regression of metastatic melanoma lesions. This study suggests the therapeutic potential of genetically engineered cells for the biologic therapy of cancer.

Original languageEnglish (US)
Pages (from-to)126-129
Number of pages4
JournalScience
Volume314
Issue number5796
DOIs
StatePublished - Oct 6 2006
Externally publishedYes

Fingerprint

Patient Transfer
Lymphocytes
Adoptive Transfer
Melanoma
Neoplasms
Biological Therapy
Retroviridae
Cell- and Tissue-Based Therapy
T-Cell Antigen Receptor
Immunotherapy
T-Lymphocytes
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., ... Rosenberg, S. A. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314(5796), 126-129. https://doi.org/10.1126/science.1129003

Cancer regression in patients after transfer of genetically engineered lymphocytes. / Morgan, Richard A.; Dudley, Mark E.; Wunderlich, John R.; Hughes, Marybeth S.; Yang, James C.; Sherry, Richard M.; Royal, Richard E.; Topalian, Suzanne; Kammula, Udai S.; Restifo, Nicholas P.; Zheng, Zhili; Nahvi, Azam; De Vries, Christiaan R.; Rogers-Freezer, Linda J.; Mavroukakis, Sharon A.; Rosenberg, Steven A.

In: Science, Vol. 314, No. 5796, 06.10.2006, p. 126-129.

Research output: Contribution to journalArticle

Morgan, RA, Dudley, ME, Wunderlich, JR, Hughes, MS, Yang, JC, Sherry, RM, Royal, RE, Topalian, S, Kammula, US, Restifo, NP, Zheng, Z, Nahvi, A, De Vries, CR, Rogers-Freezer, LJ, Mavroukakis, SA & Rosenberg, SA 2006, 'Cancer regression in patients after transfer of genetically engineered lymphocytes', Science, vol. 314, no. 5796, pp. 126-129. https://doi.org/10.1126/science.1129003
Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006 Oct 6;314(5796):126-129. https://doi.org/10.1126/science.1129003
Morgan, Richard A. ; Dudley, Mark E. ; Wunderlich, John R. ; Hughes, Marybeth S. ; Yang, James C. ; Sherry, Richard M. ; Royal, Richard E. ; Topalian, Suzanne ; Kammula, Udai S. ; Restifo, Nicholas P. ; Zheng, Zhili ; Nahvi, Azam ; De Vries, Christiaan R. ; Rogers-Freezer, Linda J. ; Mavroukakis, Sharon A. ; Rosenberg, Steven A. / Cancer regression in patients after transfer of genetically engineered lymphocytes. In: Science. 2006 ; Vol. 314, No. 5796. pp. 126-129.
@article{5d63efd3f73d4ff1962e66c6ca91608b,
title = "Cancer regression in patients after transfer of genetically engineered lymphocytes",
abstract = "Through the adoptive transfer of lymphocytes after host immunodepletion, it is possible to mediate objective cancer regression in human patients with metastatic melanoma. However, the generation of tumor-specific T cells in this mode of immunotherapy is often limiting. Here we report the ability to specifically confer tumor recognition by autologous lymphocytes from peripheral blood by using a retrovirus that encodes a T cell receptor. Adoptive transfer of these transduced cells in 15 patients resulted in durable engraftment at levels exceeding 10{\%} of peripheral blood lymphocytes for at least 2 months after the infusion. We observed high sustained levels of circulating, engineered cells at 1 year after infusion in two patients who both demonstrated objective regression of metastatic melanoma lesions. This study suggests the therapeutic potential of genetically engineered cells for the biologic therapy of cancer.",
author = "Morgan, {Richard A.} and Dudley, {Mark E.} and Wunderlich, {John R.} and Hughes, {Marybeth S.} and Yang, {James C.} and Sherry, {Richard M.} and Royal, {Richard E.} and Suzanne Topalian and Kammula, {Udai S.} and Restifo, {Nicholas P.} and Zhili Zheng and Azam Nahvi and {De Vries}, {Christiaan R.} and Rogers-Freezer, {Linda J.} and Mavroukakis, {Sharon A.} and Rosenberg, {Steven A.}",
year = "2006",
month = "10",
day = "6",
doi = "10.1126/science.1129003",
language = "English (US)",
volume = "314",
pages = "126--129",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "5796",

}

TY - JOUR

T1 - Cancer regression in patients after transfer of genetically engineered lymphocytes

AU - Morgan, Richard A.

AU - Dudley, Mark E.

AU - Wunderlich, John R.

AU - Hughes, Marybeth S.

AU - Yang, James C.

AU - Sherry, Richard M.

AU - Royal, Richard E.

AU - Topalian, Suzanne

AU - Kammula, Udai S.

AU - Restifo, Nicholas P.

AU - Zheng, Zhili

AU - Nahvi, Azam

AU - De Vries, Christiaan R.

AU - Rogers-Freezer, Linda J.

AU - Mavroukakis, Sharon A.

AU - Rosenberg, Steven A.

PY - 2006/10/6

Y1 - 2006/10/6

N2 - Through the adoptive transfer of lymphocytes after host immunodepletion, it is possible to mediate objective cancer regression in human patients with metastatic melanoma. However, the generation of tumor-specific T cells in this mode of immunotherapy is often limiting. Here we report the ability to specifically confer tumor recognition by autologous lymphocytes from peripheral blood by using a retrovirus that encodes a T cell receptor. Adoptive transfer of these transduced cells in 15 patients resulted in durable engraftment at levels exceeding 10% of peripheral blood lymphocytes for at least 2 months after the infusion. We observed high sustained levels of circulating, engineered cells at 1 year after infusion in two patients who both demonstrated objective regression of metastatic melanoma lesions. This study suggests the therapeutic potential of genetically engineered cells for the biologic therapy of cancer.

AB - Through the adoptive transfer of lymphocytes after host immunodepletion, it is possible to mediate objective cancer regression in human patients with metastatic melanoma. However, the generation of tumor-specific T cells in this mode of immunotherapy is often limiting. Here we report the ability to specifically confer tumor recognition by autologous lymphocytes from peripheral blood by using a retrovirus that encodes a T cell receptor. Adoptive transfer of these transduced cells in 15 patients resulted in durable engraftment at levels exceeding 10% of peripheral blood lymphocytes for at least 2 months after the infusion. We observed high sustained levels of circulating, engineered cells at 1 year after infusion in two patients who both demonstrated objective regression of metastatic melanoma lesions. This study suggests the therapeutic potential of genetically engineered cells for the biologic therapy of cancer.

UR - http://www.scopus.com/inward/record.url?scp=33749624177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749624177&partnerID=8YFLogxK

U2 - 10.1126/science.1129003

DO - 10.1126/science.1129003

M3 - Article

C2 - 16946036

AN - SCOPUS:33749624177

VL - 314

SP - 126

EP - 129

JO - Science

JF - Science

SN - 0036-8075

IS - 5796

ER -